VIVUS INC. overview

VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules PR Newswire PLANO, Texas, April 3, 2020 PLANO, Texas , April 3, 2020 /PRNewswire/ -- VitalTech , a rapidly growing market leader in Virtual Care, announced today its partnership with VIVUS, Inc , a publicly held biopharmaceutical company (Nasdaq: VVUS). Leveraging VitalTech's industry-leading virtual care platform and comprehensive medical device product line, VIVUS plans to...

...

...

CAMPBELL, Calif. and CHARLOTTE, N.C., May 15, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc., today announced a partnership to facilitate access to PANCREAZE ® (pancrelipase) Delayed Release Capsules for uninsured or underinsured patients with exocrine pancreatic insufficiency (EPI) that meet applicable eligibility criteria. The Company intends to make PANCREAZE available to eligible patients through the VIVUS...

Company to host conference call today at 4:30pm ET CAMPBELL, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for the quarter ended March 31, 2019 and provided a business update. “The first quarter of 2019 represents the completion of the third...

CAMPBELL, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2019 after the market close on Tuesday, April 30, 2019. The company will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT the same day to review results and provide a business update. To listen via webcast, please visit http://ir.vivus.com/ , or by clicking here . To listen via phone, please use...

CAMPBELL, CA / ACCESSWIRE / March 14, 2019 / VIVUS, Inc. (NASDAQ: VVUS; the "Company"), a biopharmaceutical company, today announced that the Ministry of Health of the Russian Federation has approved 50 mg, 100 mg and 200 mg tablets of avanafil for the treatment of erectile dysfunction (ED). The product will be marketed in the Russian Federation under the brand name RAZATUS. "The approval of avanafil in the Russian Federation adds to the growing list of territories in which the product is now...

...